Rachel Harvey

Industry Partnerships and Commercialisation Officer, Medicine

Rachel is primarily focused on building partnerships with organisations in the pharmaceutical sector; connecting partners with academics of interest, shaping and negotiating research collaborations and facilitating industry-led open innovation calls. Rachel also manages out-licensing of a portfolio of Faculty of Medicine technologies, primarily novel therapeutics.

Rachel joined Imperial in 2017 as part of the Management Trainee Graduate Scheme, and has been with the IPC FoM team since February 2020. Rachel holds a BSc in Biomedical Science from the University of Manchester.

Rachel's portfolio

Dual DNA-PK/AKT inhibition for the treatment of platinum-resistant cancer

Dual DNA-PK/AKT inhibition for the treatment of platinum-resistant cancer

Novel compounds with dual DNA-PK/AKT inhibitor activity for the treatment of platinum-resistant cancers. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...